Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369473 | PMC |
| http://dx.doi.org/10.1136/flgastro-2015-100596 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exosomes: Key Messengers Mediating the Interaction Between Tumor Cells and CD8 T Cells in the Tumor Microenvironment.
Int J Nanomedicine
January 2025
Department of Thoracic Surgery, the First Hospital of China Medical University, Shenyang, 110002, People's Republic of China.
In recent years, with an increasingly profound comprehension of the tumor microenvironment, it has been discovered that the constituent cells within the immune microenvironment, such as macrophages, CD4T cells, and CD8T cells, interact with tumor cells in manners conducive to tumorigenesis and progression. Exosomes play a pivotal role as essential mediators for intercellular material exchange and signal transmission in this context. Tumor cell-derived exosomes carrying cargo such as PD-L1 and ncRNAs engage with CD8T cells to induce cytotoxic responses and facilitate immune evasion, thereby promoting tumor advancement.
View Article and Find Full Text PDFBiS/BiO(OH) nanorods with internal electric field throughout the entire bulk phase as photoelectrochemical sensing platforms for CYFRA21-1 immunoassay.
Anal Chim Acta
February 2025
Key Laboratory of Chemical Sensing & Analysis in Universities of Shandong, School of Chemistry and Chemical Engineering, University of Jinan, 250022, Jinan, PR China; Department of Chemistry, Sungkyunkwan University, 16419, Suwon, Republic of Korea. Electronic address:
Photoelectrochemical (PEC) immunosensors are highly promising tools for monitoring biochemical molecules. Constructing high-performance heterojunctions is a general method to improve the sensitivity of PEC immunosensors. The internal electric field (IEF) formed at the heterojunction interface plays a crucial role in coordinating the separation of photogenerated carriers.
View Article and Find Full Text PDFAssessment of MpoxPlex, a high-throughput and multiplexed immunoassay: a diagnostic accuracy study.
Lancet Microbe
January 2025
Emerging Pathogen Serology Group, Vaccine Development Evaluation and Preparedness Centre, UK Health Security Agency, Wiltshire, UK.
Background: In May, 2022, the first global outbreak of mpox (formerly known as monkeypox) occurred. In response, public health agencies in the UK have made smallpox vaccines available to individuals at the highest risk of infection. With mpox cases still being detected globally, novel tools are required to aid with diagnosis, serosurveillance, and the evaluation of immune responses following infection and immunisation with current and new vaccine candidates.
View Article and Find Full Text PDFAssessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab".
Clin Rheumatol
January 2025
Department of Public Health, University of Murcia, Campus de Ciencias de la Salud, Murcia, 30120, Spain.
Introduction: Therapeutic drug monitoring (TDM) in inflammatory rheumatic diseases (RMDs) is gaining interest. However, there are unresolved questions about the best practices for implementing TDM effectively in clinical settings.
Objective: The primary objective of this study was to evaluate whether early TDM of adalimumab predicts drug survival at 52 weeks in patients with RMDs.
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!